Sutekast 25mg Capsules: Advanced Clinical Insights, Global Procurement, and Export Solutions
In the specialized field of targeted oncology, Sutekast 25mg (Sunitinib) stands as a pivotal multi-kinase inhibitor. For oncology clinics, institutional pharmacies, and licensed pharmaceutical distributors in the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, establishing a seamless supply chain for high-quality Sunitinib is critical for patient outcomes.
As a leading pharmaceutical exporter from India, Ernest Oncology facilitates the international distribution of Sutekast 25mg, ensuring that medical institutions worldwide have access to WHO-GMP-certified oncology care.
Detailed Product Information: Sutekast 25mg
Sutekast 25 mg is an oral therapeutic agent containing Sunitinib Malate, manufactured by Aprazer Healthcare. It is a generic version of the reference drug Sutent and is widely utilized for its precision in targeting cancer cells while minimizing damage to healthy tissue.
Clinical Indications
Advanced Renal Cell Carcinoma (RCC): Sutekast is a primary treatment for metastatic kidney cancer, proven to inhibit tumor growth and prolong progression-free survival.
Gastrointestinal Stromal Tumor (GIST): Specifically indicated for patients who have progressed on or are intolerant to imatinib therapy.
Pancreatic Neuroendocrine Tumors (pNET): Utilized for progressive, well-differentiated tumors in the pancreas that are surgically unresectable.
Adjuvant Treatment: In certain clinical settings, it is used to reduce the risk of cancer returning after a nephrectomy.
Pharmacodynamics & Mechanism of Action
Sutekast 25 mg works by inhibiting multiple receptor tyrosine kinases (RTKs). These receptors are essential for tumor signaling and the formation of new blood vessels.
Anti-Angiogenesis: By blocking VEGFR and PDGFR, the medication effectively starves the tumor by preventing the development of its blood supply.
Cellular Proliferation Inhibition: It interrupts the chemical signals that allow cancer cells to multiply and metastasize
Why Source Sutekast 25 mg from Ernest Oncology?
Sourcing through Ernest Oncology provides several strategic advantages for international buyers:
Quality Assurance: Sutekast is produced in state-of-the-art facilities that meet global manufacturing standards (GMP).
Customs & Compliance: We manage complex export documentation, including Certificate of Origin (COO) and clinical data sheets, ensuring seamless customs clearance in the UK, USA, and UAE.
Cold-Chain Expertise: Specialized packaging and logistics ensure the therapeutic integrity of Sutekast 25 mg is maintained throughout the international journey.
Competitive Bulk Pricing: Our scale allows us to offer institutional buyers highly competitive rates for bulk pharmaceutical procurement.
Administration and Safety Guidelines
Dosage: The 25 mg strength allows for flexible dosing as prescribed by an oncologist. For RCC/GIST, the standard cycle is often 50 mg (two 25 mg capsules) daily for 4 weeks, followed by a 2-week rest.
Monitoring: Patients should undergo regular monitoring for blood pressure, thyroid function, and cardiac health while on Sunitinib therapy.
Storage: Store in a cool, dry place below 30°C. Protect from direct sunlight and keep out of reach of children.
📞 Contact Ernest Oncology—Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD]
For bulk inquiries, official quotes, and global shipping timelines for Sutekast 25 mg Capsules, reach out to our dedicated export team today.
🌐 Websites:
📧 Email:
exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp:
+91 93599 02383 🔗 Direct Chat:
https://wa.me/919359902383
